A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose
A phase 1/2 trial of Linvoseltamab in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting.
Overview
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment is a phase 1/2 interventional study registered as NCT05828511 by Regeneron Pharmaceuticals, with 149 participants planned, started 2023-12-19 and due to reach its primary completion in 2035-11-02. Interventions recorded: Linvoseltamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- TrialA Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- TrialA Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- TrialA Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- TrialA Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- TrialLINKER-MM1
Shares Linvoseltamab, Multiple myeloma.
- TrialA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- PairingCaution: T-cell redirectors and infections
Shares Linvoseltamab, Multiple myeloma.